Anti-CD44v6 [BIWA4]

Absolute Antibody

Anti-CD44v6 [BIWA4]

9

The binding affinity of the antibody to CD44v6 was measured by surface plasmon resonance. The antibody showed a specificity of tumor localization when administrated together with another anti-CD44v6 antibody in mice in in vivo experiments (Verel et al. 2002; PMID: 11992408). The specificity of the humanized version of the antibody was confirmed by ELISA anlaysis (Kd= 3.4 nM). The antibody had good therapeutic efficacy, biodistribution and tumor uptake in in vivo experiments in mice. Mice treated with 186Re-BIWA 4 showed a decreased in the tumor volume (US6972324B2). The radioactively labelled humanized version of the antibody was employed in a clinical trial in patients with advanced squamous cell carcinoma of the head and neck showing promising antitumor effects (Boerjesson et al., 2003; PMID: 14506195).

ELISA, Other Application

Research Use Only

Monoclonal

BIWA4

CD44

CD44 molecule (IN blood group)

CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL, HUTCH-1, HUTCH-I, Hermes-1, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CD44 antigen, CD44 molecule (Indian blood group), GP90 lymphocyte homing/adhesion receptor, Hermes antigen, In(Lu) related-p80, Indian blood group antigen, cell surface glycoprotein CD44, chondroitin sulfate proteoglycan 8, epican, extracellular matrix receptor III, hematopoietic cell E- and L-selectin ligand, heparan sulfate proteoglycan, homing cell adhesion molecule, homing function and Indian blood group system, hyaluronate receptor, phagocyte glycoprotein 1, phagocytic glycoprotein 1, soluble CD44

Mouse

IgG1

CD44 antigen

Human

-20°C,2°C to 8°C

12352203